MX2020013833A - Composiciones y metodos para el tratamiento de hemoglobinopatias y talasemias. - Google Patents

Composiciones y metodos para el tratamiento de hemoglobinopatias y talasemias.

Info

Publication number
MX2020013833A
MX2020013833A MX2020013833A MX2020013833A MX2020013833A MX 2020013833 A MX2020013833 A MX 2020013833A MX 2020013833 A MX2020013833 A MX 2020013833A MX 2020013833 A MX2020013833 A MX 2020013833A MX 2020013833 A MX2020013833 A MX 2020013833A
Authority
MX
Mexico
Prior art keywords
methods
compositions
thalassemias
hemoglobinopathies
treatment
Prior art date
Application number
MX2020013833A
Other languages
English (en)
Inventor
Sean Carroll
Raffi Afeyan
Matthew Russell
Original Assignee
Axcella Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Axcella Health Inc filed Critical Axcella Health Inc
Publication of MX2020013833A publication Critical patent/MX2020013833A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/18—Peptides; Protein hydrolysates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0606—Arginine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0612—Carnitine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/062—Glutamine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0624—Histidine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0628—Leucine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/063—Lysine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0634—N-Acetyl-Cysteine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0642—Serine
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2250/00—Food ingredients
    • A23V2250/02—Acid
    • A23V2250/06—Amino acid
    • A23V2250/0654—Valine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Polymers & Plastics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación proporciona composiciones y métodos para mejorar la disfunción de eritrocitos o tratar una hemoglobinopatía o una talasemia (por ejemplo, anemia de células falciformes o ß-talasemia).
MX2020013833A 2018-06-20 2019-06-19 Composiciones y metodos para el tratamiento de hemoglobinopatias y talasemias. MX2020013833A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862687721P 2018-06-20 2018-06-20
US201962804879P 2019-02-13 2019-02-13
PCT/US2019/037925 WO2019246214A1 (en) 2018-06-20 2019-06-19 Compositions and methods for the treatment of hemoglobinopathies and thalassemias

Publications (1)

Publication Number Publication Date
MX2020013833A true MX2020013833A (es) 2021-03-25

Family

ID=67482969

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020013833A MX2020013833A (es) 2018-06-20 2019-06-19 Composiciones y metodos para el tratamiento de hemoglobinopatias y talasemias.

Country Status (20)

Country Link
US (2) US11058654B2 (es)
EP (1) EP3809881A1 (es)
JP (1) JP2021528414A (es)
KR (1) KR20210022054A (es)
CN (1) CN112654263A (es)
AU (1) AU2019290620A1 (es)
BR (1) BR112020026110A2 (es)
CA (1) CA3104279A1 (es)
CL (1) CL2020003276A1 (es)
CU (1) CU20200106A7 (es)
EA (1) EA202190073A1 (es)
EC (1) ECSP20081995A (es)
IL (1) IL279467A (es)
JO (1) JOP20200325A1 (es)
MX (1) MX2020013833A (es)
PE (1) PE20210371A1 (es)
PH (1) PH12020552212A1 (es)
SG (1) SG11202012714QA (es)
TW (1) TW202015667A (es)
WO (1) WO2019246214A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
US11617731B2 (en) 2017-04-28 2023-04-04 Axcella Health, Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
KR20200039748A (ko) 2017-08-14 2020-04-16 악셀라 헬스 인크. 간 질환 치료를 위한 아미노산 조성물
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
CN112823018A (zh) 2018-06-20 2021-05-18 胺细拉健康公司 制备氨基酸组合物的方法
US20230000808A1 (en) * 2019-12-06 2023-01-05 Axcella Health Inc. Compositions and methods excluding or with reduced glutamine for the treatment of hemoglobinopathies and thalassemias
CN112336710A (zh) * 2020-12-27 2021-02-09 西北农林科技大学 谷氨酰胺在制备防治葛根素注射剂诱发的血管内溶血的药物上的应用
WO2023009444A1 (en) 2021-07-26 2023-02-02 Axcella Health Inc. Amino acid compositions and methods for use in the treatment of post-acute sequelae of covid-19

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6087398A (en) * 1996-03-01 2000-07-11 South Alabama Medical Science Foundation Sickle cell anemia treatment
US5693671A (en) * 1996-05-01 1997-12-02 Harbor-Ucla Research And Education Institute L-glutamine therapy for sickle cell diseases and thalassemia
US6028107A (en) * 1997-02-27 2000-02-22 Waugh; William Howard Orthomolecular medical use of L-citrulline for vasoprotection, relaxative smooth muscle tone and cell protection
US6251927B1 (en) 1999-04-20 2001-06-26 Medinox, Inc. Methods for treatment of sickle cell anemia
EP1372641A4 (en) 2001-03-05 2004-08-25 Stephen P Ernest ENTERAL FORMULATION
US7445807B2 (en) * 2002-10-15 2008-11-04 Western Holdings, Llc Agglomerated granular protein-rich nutritional supplement
WO2004073623A2 (en) 2003-02-14 2004-09-02 Children's Hospital & Research Center At Oakland Treatment of conditions associated with decreased nitric oxide bioavailability, including elevated arginase conditions
WO2005017094A2 (en) 2003-08-19 2005-02-24 Bioadvantex Pharma Inc. N-acetyl compositions as adjunct therapy for treatment and prevention of cysteine/glutathione deficiency
JP2005272410A (ja) * 2004-03-26 2005-10-06 Ajinomoto Co Inc 抗動脈硬化用及び／又は血液レオロジー改善用経口アミノ酸組成物
WO2006002096A2 (en) 2004-06-18 2006-01-05 Vivo Therapeutics, Inc. Low doses of l-citrulline for treating diseases
EP1825261B1 (en) 2004-12-01 2011-07-20 Children's Hospital & Research Center at Oakland Diagnosis of conditions associated with decreased arginine bioavailability
AU2006238888A1 (en) 2005-04-21 2006-11-02 Glenn A. Goldstein N-acetylcysteine amide (NAC amide) for the treatment of diseases and conditions associated with oxidative stress
US20120316121A1 (en) 2005-07-28 2012-12-13 Allen Ann De Wees Materials and Methods for Modulating Arginine Metabolism
JP5316918B2 (ja) * 2006-04-24 2013-10-16 味の素株式会社 透析患者用輸液剤
US20070286909A1 (en) 2006-06-07 2007-12-13 Daniel S. Smith Amino acid compositions
WO2008054788A2 (en) * 2006-10-31 2008-05-08 Chrono Therapeutics, Inc. Transdermal delivery techniques for drugs, nutraceuticals and other active substances
CN100518815C (zh) * 2007-02-15 2009-07-29 北京苏里曼医药科技有限公司 一种氨基酸组合物
US20090306209A1 (en) * 2008-06-04 2009-12-10 Daugherty F Joseph Enteric-coated formulations of polyethylene glycol and one or more soluble amino acids for oral ingestion and enhanced uptake of same
US8840950B2 (en) 2010-05-26 2014-09-23 Jacqueline M. Hibbert Compositions of nutrition supplementation for nutritional deficiencies and method of use therefore
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
EP2779842B1 (en) 2011-11-15 2017-09-20 TIMA Foundation Composition for protection against cell-damaging effects
JP6060176B2 (ja) 2011-12-19 2017-01-11 エマウス メディカル インコーポレイテッド 憩室症の治療のための方法及び組成物
US8980823B2 (en) 2012-03-07 2015-03-17 Shaker A. Mousa Formulations of Factor VIIa inhibitors and utility
US9597367B2 (en) * 2013-04-19 2017-03-21 Bioventures, Llc Methods for improving muscle and heart function
WO2015034984A1 (en) * 2013-09-05 2015-03-12 Emory University Nutritional formulas comprising medium chain fatty acids or esters thereof and methods related thereto
US20180125926A1 (en) 2013-09-25 2018-05-10 Axcella Health Inc. Compositions and Formulations and Methods of Production and Use Thereof
AU2014324900A1 (en) 2013-09-25 2016-05-19 Axcella Health Inc. Compositions and formulations for prevention and reduction of tumorigenesis, cancer cell proliferation and invasion, and methods of production and use thereof in cancer treatment
EP3626707A1 (en) 2014-01-13 2020-03-25 The General Hospital Corporation Heteroaryl disulfide compounds as allosteric effectors for increasing the oxygen-binding affinity of hemoglobin
WO2015127163A1 (en) 2014-02-20 2015-08-27 Phd Biosciences ( Formerly Nanometics Llc) Pyridoxamine for the treatment of sickle cell disease, thalassemia and related blood diseases
MA39927B1 (fr) * 2014-04-30 2018-09-28 Hoffmann La Roche Inhibiteurs de glyt1 pour le traitement de troubles hématologiques
WO2015187649A1 (en) 2014-06-03 2015-12-10 Sulfagenix, Inc. Methods and compositions for treating nitric oxide deficiency disorders and related conditions
WO2016033187A1 (en) 2014-08-26 2016-03-03 The Brigham And Women's Hospital, Inc. Use of gelsolin in the treatment and diagnosis of sickle cell disease
US9822190B2 (en) 2015-01-29 2017-11-21 Shaker A. Mousa Compositions and method for anti-sickling of red blood cells in sickle cell disease
EP3493796A1 (en) 2016-08-05 2019-06-12 Fresenius Kabi Deutschland GmbH Glutamine for preserving, improving or restoring kidney function
JOP20190147A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض واضطرابات العضلات
JOP20190146A1 (ar) 2016-12-19 2019-06-18 Axcella Health Inc تركيبات حمض أميني وطرق لمعالجة أمراض الكبد
AR111082A1 (es) 2017-02-27 2019-05-29 Univ Vanderbilt Citrulina para el tratamiento de la crisis de células falciformes
US11617731B2 (en) 2017-04-28 2023-04-04 Axcella Health, Inc. Amino acid compositions and their use for the treatment of traumatic brain injury
MX2020001766A (es) 2017-08-14 2020-07-29 Axcella Health Inc Composiciones de aminoacidos para el tratamiento de lesion neuronal.
KR20200039748A (ko) 2017-08-14 2020-04-16 악셀라 헬스 인크. 간 질환 치료를 위한 아미노산 조성물
CU20200106A7 (es) 2018-06-20 2021-08-06 Axcella Health Inc Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias
AR116213A1 (es) 2018-06-20 2021-04-14 Axcella Health Inc Composiciones para terapia y salud que contienen aminoácidos con sabor amargo
CN112823018A (zh) 2018-06-20 2021-05-18 胺细拉健康公司 制备氨基酸组合物的方法
EP3810123A1 (en) 2018-06-20 2021-04-28 Axcella Health Inc. Compositions and methods for the treatment of fat infiltration in muscle
US20190388377A1 (en) 2018-06-20 2019-12-26 Axcella Health Inc. Compositions and methods for the treatment of liver diseases and disorders

Also Published As

Publication number Publication date
WO2019246214A8 (en) 2020-02-20
SG11202012714QA (en) 2021-01-28
IL279467A (en) 2021-01-31
JOP20200325A1 (ar) 2020-12-14
PE20210371A1 (es) 2021-02-26
US20210290574A1 (en) 2021-09-23
CU20200106A7 (es) 2021-08-06
TW202015667A (zh) 2020-05-01
CA3104279A1 (en) 2019-12-26
JP2021528414A (ja) 2021-10-21
AU2019290620A1 (en) 2021-01-14
PH12020552212A1 (en) 2021-08-16
EP3809881A1 (en) 2021-04-28
CL2020003276A1 (es) 2021-07-09
ECSP20081995A (es) 2021-01-29
WO2019246214A1 (en) 2019-12-26
KR20210022054A (ko) 2021-03-02
US20190388376A1 (en) 2019-12-26
US11058654B2 (en) 2021-07-13
EA202190073A1 (ru) 2021-04-12
CN112654263A (zh) 2021-04-13
BR112020026110A2 (pt) 2021-03-16

Similar Documents

Publication Publication Date Title
MX2020013833A (es) Composiciones y metodos para el tratamiento de hemoglobinopatias y talasemias.
MX2019015580A (es) Metodos para tratar la enfermedad de huntington.
MY196582A (en) PD-1/PD-L1 Inhibitors
MX2020009957A (es) Compuestos para el tratamiento de enfermedad de hungtinton.
MX2022002877A (es) Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
MX2017012512A (es) Moléculas que tienen utilidad plaguicida, e intermediarios, composiciones y procesos, relacionados con ellas.
MX2020010369A (es) Particulas implantables y metodos relacionados.
WO2018134787A3 (en) Compositions and methods for the depletion of cd137+ cells
MX2021013854A (es) Compuestos para tratar enfermedad de huntington.
MX2020000342A (es) Anticuerpos agonistas que se unen a cd137 humano y sus usos.
EA202092086A1 (ru) Ингибиторы аргиназы
PH12021550558A1 (en) Modulators of pnpla3 expression
CR20200631A (es) Modulares de la expresión de apol1
PH12019502174A1 (en) Modulators of pcsk9 expression
ZA202004679B (en) Regeneration of genetically modified plants
MX2021013913A (es) Composiciones y metodos para el tratamiento de enfermedades mediadas por atpasa.
MX2022004024A (es) Metodos y materiales para el tratamiento de la neurotoxicidad.
PH12021551053A1 (en) Modulators of irf5 expression
MX2020013510A (es) Composiciones para tratamiento, y metodos para fabricar y usar las mismas.
ZA202106519B (en) Caspase inhibitors and methods of use thereof
JOP20210107A1 (ar) مضمنات التعبير عن foxp3
MX2020007369A (es) Moduladores de la expresion de dnm2.
MX2020010721A (es) Moduladores de la expresion de ezh2.
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
AR117593A1 (es) Composiciones y métodos para el tratamiento de hemoglobinopatías y talasemias